Inflammatory bowel disease (IBD) afflicts 5 million people and is increasing in prevalence. There is an unmet clinical need for safer and effective treatments for IBD. The BT-11 is a small molecule oral therapeutic that ameliorates IBD by targeting lanthionine synthetase C-like 2 (LANCL2) and has a benign safety profile in rats.
NImmune Biopharma Presented New Data at ACG 2026 Supporting the Efficacy and Safety of Innovative LANCL2 Medicines Targeting a Novel Mechanism in Hard-to-Treat IBD
NImmune Biopharma Presented New Data at ACG 2026 Supporting the Efficacy and Safety of Innovative LANCL2 Medicines Targeting a Novel Mechanism in Hard-to-Treat IBD
Download Press Release New clinical data show omilancor reduced a molecular signature associated with biologic refractoriness by more than 55% in ulcerative colitis and Crohn’s disease patients Omilancor and NIM-1324 reduced disease severity, pathology and...
